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Oxadiazole derivates play vital role in biological field such 
as anti-microbial, anti-viral, anti-tubercular, anti-
inflammatory and anti-convulsant activity. Therapeutic 
significance of these clinically useful drugs in treatment of 
inflammation encouraged the development of some more 
potent and significant compounds. oxadiazole derivatives 
are remarkably effective compounds for inflammation and 
analgesic activity. Extensive biochemical and 
pharmacological studies have confirmed that these 
molecules are effective in inflammation. This 
comprehensive overview summarizes the chemistry of 
different derivatives of substituted oxadiazole along with 
their anti-inflammatory activity. 
KEYWORDS: Oxadiazole derivatives, Chemistry, Design, 
Anti-inflammatory activity.  
 
INTRODUCTION 
 Heterocyclic compounds containing the five-
membered oxadiazole nucleus possess a diversity of useful 
biological effects. 1, 3, 4-Oxadiazole are important because 
of their versatile biological actions. In particular, 
compounds bearing the 1, 3, 4-oxadiazole nucleus is known 
to have unique antioedema and anti-inflammatory activities 
[1-4]. Differently substituted oxadiazole moieties have also 
been found to have other interesting activities such as 
analgesic [3-4], antimicrobial [5], antitubercular [6], 
anticonvulsant [7] and anti-hepatitis B viral activities [8]. 
Non-steroidal anti-inflammatory drugs NSAIDs form a 
class of therapeutic agents that are most widely used 
because of their anti-inflammatory, analgesic and 
antipyretic effects. The prevalent side effects of NSAIDs 
are the occurrence of gastrointestinal side effects like 
gastric upset, irritation and ulceration [9]. Substituted 
oxadiazole derivatives have been studied and proved to be 
potent CO/5-LO inhibitors [10-15]. This novel dual 
inhibitory activity of the enzyme pathways holds promise 
as anti-inflammatory agents with an improved efficacy and 
safety profile. 
1. SYNTHESIS AND ANTIINFLAMATORY 
ACTIVITY OF SOME 1, 3, 4 OXADIAZOLE 
DERIVATIVES 
 A series of substituted 1, 3, 4-oxadiazole 
derivatives were synthesized as anti-inflammatory and 
analgesic agents. The target compounds were obtained by 
cyclodesulfurization of the corresponding 
thiosemicarbazides using either dicyclohexylcarbodiimide 
DCC, or I2/NaOH. Intermediates thiosemicarbazides are 
readily accessible through conversion of the carboxylic  
 
acids to the respective hydrazides followed by treatment 
with appropriate isothiocyanate derivatives. The structures 
of the synthesized compounds were confirmed by 
elemental as well as spectroscopic analyses. The anti-
inflammatory activity was investigated by determination of 
the inhibitory effects of the oxadiazole derivatives on 
histamine-induced edema in rat abdomen [10] 
 
Synthesis of Substituted thiosemicarbazide derivatives 
(3) 
 To a solution of the acid hydrazide 2 (4.4 mmol) 
in hot ethanol (40 mL) was added equivalent amount of the 
appropriate isothiocyanate in ethanol (10 mL) and the 
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mixture was refluxed with stirring for 30 min. The 
products, which either precipitated during reflux or after 
cooling to room temperature, were-filtered and-crystallized 
from the proper solvent [10].  
Synthesis of 2, 5-Disubstituted-1, 3, 4-oxadiazole 
derivatives (4) 
 To a stirred, cooled (0-5°C) solution of the 
respective thiosemicarbazide derivative (5 mmol) in 
ethanol (30 mL), was added 2N sodium hydroxide until the 
solution aquired pH 9. Iodine in potassium iodide solution 
(5%) was then added drop wise with stirring at room 
temperature until the yellow colour of iodine persisted. The 
solvent was removed under reduced pressure and the 
mixture cooled to precipitate the corresponding oxadiazole 
derivative. The products were then filtered, washed with 
water and carbon disulfide, dried and crystallized from the 
proper solvent [10]. 
Anti-inflammatory activity 
 The anti-inflammatory activity of the synthesized 
1, 3, 4-oxadiazole derivatives 4a-4f was evaluated using 
Golikov’s method [16]. Intradermally injected histamine 
was used as the phlogogenic substance and trypan blue (IV) 
as indicator. The increase in the time elapsed until the 
appearance of the blue colour at the site of injection of 
histamine v/s control was taken as a measure of the anti-
inflammatory activity of the tested compounds and the 
reference standard drug (ibuprofen). Among the 
significantly active compounds, the oxadiazole derivatives 
4a-4f were the most potent and exhibited higher anti-
inflammatory activity than ibuprofen, the standard 
reference drug [10]. 
2. SYNTHESIS AND ANTIINFLAMATORY 
ACTIVITY OF SOME NOVEL 1, 3, 4 OXADIAZOLE 
DERIVATIVES 
. Derivatization of the carboxylate function of some 
NSAIDs resulted in an increased anti-inflammatory activity 
with a reduced ulcerogenic effect. Hence, it is not irrelevant 
to speculate that replacing the terminal carboxylic function 
of 3-(4-bromobenzoyl) propionic acid by oxadiazole ring 
may enhance the anti-inflammatory activity of such 
compounds. Therefore, it was considered worthwhile to 
synthesize some new 3-(4-bromobenzoyl) propionic acid 
derivatives by incorporating the oxadiazolyl moiety to get 
better anti-inflammatory molecules [1]. A novel series of 2-
[3-(4-bromophenyl)propan-3-one]-5-(substituted phenyl)-
1,3,4-oxadiazoles (4a-n) have been synthesized from 3-(4-
bromobenzoyl)propionic acid (3) with the aim to get better 
anti-inflammatory and analgesic agents with minimum or 
without side effects (ulcerogenicity). Compound 3 was 
reacted with several aryl acid hydrazides (2a-n) in 
phosphorous oxychloride to obtain the title compounds. 
 
Synthesis of 3-(4-Bromobenzoyl) propionic acid 
(Friedel-Craft’s acylation reaction) (2) 
To a solution of succinic anhydride (0.1mol) in 
bromobenzene (50 mL), anhydrous aluminium chloride 
(0.11mol) was added in small portions over a period of 2 h 
under stirring. The reaction mixture was then refluxed for 
two hours and after completion of the reaction, excess 
bromobenzene was removed by steam distillation. It was 
purified by dissolving in sodium hydroxide solution, 
filtering, followed by addition of hydrochloric acid. The 
solid so obtained was filtered, washed with cold water, 
dried and crystallized from methanol to give a cream 
colored product, which gave effervescence with sodium 
bicarbonate solution [1]. 
Synthesis of 2-[3-(4-Bromophenyl) propan-3-one]-5-
(substituted phenyl)-1, 3, 4-oxadiazoles (3) 
Appropriate aryl acid hydrazide (1 mmol) was dissolved in 
phosphorous oxychloride (5 mL) and 3-(4-bromobenzoyl) 
propionic acid (2) (1 mmol) was added. The reaction 
mixture, after refluxing for 5 h, was cooled to room 
temperature and poured onto crushed ice. On neutralization 
of the contents with sodium bicarbonate solution (20 %), a 
solid separated out and was filtered, washed with water and 
dried. It was crystallized from methanol to give 2-[3-(4-
bromophenyl) propan-3-one]-(substituted phenyl)-1, 3, 4-
oxadiazoles [1]. 
Anti-inflammatory activity 
 This activity was tested according to the Carrageenin-
induced rat paw edema method on Wistar rats [17]. The 
rats were divided into thirteen groups of six animals each. 
Freshly prepared aqueous suspension of carrageenean (1 % 
m/V, 0.1 mL) was injected in the planta aponeurosis of the 
right hind paw of each rat. One group was kept as a control 
and the animals of other groups were pretreated with test 
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drugs (20 mg kg–1 body mass) given orally 30 minutes 
before carrageenean injection. The foot volume was 
measured before and 4 h after carrageenean injection with a 
plethysmograph. The mean increase in the paw volume in 
each group was calculated. Indomethacin and compound 3 
were used as standard drugs for comparison. Two 
compounds, 2-[3-(4-bromophenyl)- propan-3-one]-5-(4-
chlorophenyl)-1,3,4-oxadiazole (3c) and 2-[3-(4-
bromophenyl) propan-3-one]-5-(3,4-dimethoxy phenyl)-
1,3,4-oxadiazole (3f) with anti-inflammatory activity of 
59.5 and 61.9 %, respectively, were found to have 
comparable activity with that of indomethacin which 
showed 64.3 % activity at the same dose of 20 mg kg–1. 
3. SYNTHESIS AND ANTIINFLAMMATORY 
ACTIVITY OF NOVEL S-SUBSTITUTED 
PHENACYL-1, 3, 4-OXADIAZOLE-2-THIOL 
Synthetic approaches based upon chemical modification of 
NSAIDs have been taken with the aim of improving safety 
profile and in turn therapeutic window of this NSAID. 
Several studies have described the derivatization of the 
carboxylate function of representative NSAID with less 
acidic azoles, viz. 1, 3, 4-oxadiazole, Triazole, etc. which 
resulted in an increased anti-inflammatory activity with 
reduced ulcerogenicity. we have replaced the carboxylic 
acid group of diclofenac acid with less acidic heterocycle, 
1,3,4-oxadiazole, in order to accentuate potency and reduce 
GI toxicities associated with the parent diclofenac due to its 
free –COOH group. 
The pharmacological activity of NSAIDs is related to the 
suppression of prostaglandin biosynthesis from arachidonic 
acid by inhibiting the enzyme prostaglandin 
endoperoxidase, popularly known as cyclo-oxygenase 
(COX) [18-20]. It was discovered that COX exists in two 
isoforms, COX-1 and COX-2, which are regulated and 
expressed differently [18, 21-23]. COX-1 provides 
cytoprotection in the gastrointestinal tract (GIT), whereas 
inducible COX-2 selectively mediates inflammatory signals 
[18, 24-25]. Since most of the currently available NSAIDs 
in the market show greater selectivity for COX-1 than 
COX-2 [18, 26] 
Synthesis of 2-[(2, 6-dichloroanilino) phenyl] acetic acid 
(1) 
Diclofenac sodium (0.101 mol) was dissolved in ethano 
(2.5 mol); to this solution conc.H2SO4 was added dropwise 
to hydrolyse the salt to acid. The acid obtained was filtered, 
dried mp 153–155 °C [18]. 
Synthesis of ethyl-[2-(2, 6-dichloroanilino) phenyl] 
acetate (2) 
In a 500-ml round-bottomed flask place a mixture of 30 g 
(0.246mol) of diclofenac 1, 80 g (101 ml, 2.5mol) of 
absolute methanol and 5 g (2.7 ml) of concentrated 
sulphuric acid. Add a few small chips of porous porcelain 
attach a reflux condenser and boil the mixture gently for 4 
hours. Distil off the excess of alcohol on a water bath 
(rotary evaporator) and allow cooling. Pour the residue into 
about 250 ml of water contained in a separatory funnel and 
rinse the flask with a few ml of water which is also poured 
into the separatory funnel. If, owing to the comparatively 
slight difference between the density of the ester and of 
water, difficulty is experienced in obtaining a sharp 
separation of the lower ester layer and water, add 10-15 ml 
of carbon tetrachloride and shake the mixture in the funnel 
vigorously; upon standing, the heavy solution of methyl 
benzoate in the carbon tetrachloride separates sharply and 
rapidly at the bottom of the separatory funnel. Run off the 
lower layer carefully, reject the upper aqueous layer, return 
the methyl benzoate to the funnel and shake it with a strong 
solution of sodium hydrogen carbonate until all free acid is 
removed and no further evolution of carbon dioxide occurs. 
Wash once with water, and dry by pouring into a small dry 
conical flask containing about 5 g of magnesium sulphate. 
Stopper the flask, shake for about 5 minutes and allow 
standing for at least half an hour with occasional shaking. 
Filter the ethyl-[2-(2, 6-dichloroanilino) phenyl] acetate 2 
through a small fluted filter paper directly into a round-
bottomed flask fitted with a still-head carrying a 360 °C 
thermometer and an air condenser. Add a few boiling chips 
and distil from an air bath; raise the temperature slowly at 
first until all carbon tetrachloride has passed over and then 
heat more strongly. Collect the ethyl-[2-(2, 6-
dichloroanilino) phenyl] acetate 2 (a colourless liquid) at 
198-200 °C [27].  
Synthesis of [2-(2, 6-dichloroanilino) phenyl] acetic acid 
hydrazide (3) 
Compound 2 (0.01 mol) and hydrazine hydrate (0.02 mol) 
were refluxed in absolute ethanol (50 ml) for 20 h. The 
mixture was concentrated, cooled and poured in ice cold 
water. The solid thus separated out was filtered, dried and 
recrystallized from ethanol [28]. 
Synthesis of N-(4-Bromo benzylidenyl)-[2-(2, 6-
dichloroanilino) benzyl carbazide (preparation of Schiff 
bases) (4) 
A solution of 0.005mol of substituted benzaldehydes in 
ethanol was added a solution of 0.005mol of [2-(2, 6-
dichloroanilino) phenyl] acetic acid hydrazide in 50 ml of 
ethanol. The mixture was refluxed on a water bath for 2–
2.5 h. After cooling the mixture, the precipitate was 
filtered, dried and recrystallized from ethanol and purified 
by recrystallization from DMSO [29]. 
Synthesis of 5-[2-(2, 6-dichloroanilino) benzyl] 2-
mercapto- 1, 3, 4-oxadiazole (5)  
 
A mixture of 3 (0.005 mol), KOH (0.005 mol) and 
carbondisulphide (5 ml) in ethanol (50 ml) was refluxed on 
a steam bath for 12 h. The solution was then concentrated, 
cooled and acidified with dilute HCl. The solid mass that 
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separated out was filtered, washed with ethanol, dried and 
recrystallized from ethanol [18]. 
General procedure for the preparation of S-substituted 
phenacyl 1, 3, 4-oxadiazole-2-thiol (6a–d) 
Substituted acetophenon and pyridine was taken in round 
bottom flask and refluxe for 5-8 hrs. The product was 




Anti-inflammatory activity was evaluated using the well 
known Carrageenan induced rat paw oedema model [17] 
using groups of six animals each. A freshly prepared 
aqueous suspension of carrageenan (1.0% w/v, 0.1 ml) was 
injected in the sub-planter region of right hind paw of each 
rat. One group was kept as control and the animals of the 
other group were pretreated with the test drugs, 1 h before 
the carrageenan treatment. The volume was measured 
before and after carrageenan treatment at the 30 min. 
interval with the help of digital plethysmometer. 
Compounds 6a, 6b, 6c, and 6d exhibited very significant 
anti- inflammatory activity compared to standard drug 
diclofenac [18]. 
4. SYNTHESIS AND ANTIINFLAMMATORY 
ACTIVITY OF FENBUFEN BASED 3-[5-
(SUBSTITUTED ARYL)-1, 3, 4-OXADIAZOL-2-YL]-
1-(BIPHENYL-4-YL) PROPAN-1-ONES 
The synthesis of a series of 3-[5-(substituted aryl)-1, 3, 4-
oxadiazol-2-yl]-1-(biphenyl-4-yl) propan-1-ones derived 
from 4-oxo-4-(biphenyl-4-yl) butanoic acid (fenbufen) is 
described. These compounds were tested for their anti-
inflammatory, analgesic, ulcerogenic and lipid peroxidation 
actions. Differently substituted oxadiazole moiety has also 
been found to have other interesting activities such as 
analgesic, antibacterial, antifungal, anticonvulsant, 
anticancer, etc. [30-35]. The carboxylic acid group of 
fenbufen has been replaced with an heterocyclic groups 1, 
3, 4-oxadiazole [30]. 
Synthesis of 4-Oxo-4-(biphenyl-4-yl)butanoic acid 
(fenbufen) (2) 
To a solution of succinic anhydride (0.1mol) in biphenyl 
(50 mL), anhydrous aluminium chloride (0.11mol) was 
added in small portions over a period of 2 h under stirring. 
The reaction mixture was then refluxed for two hours and 
after completion of the reaction, excess biphenyl was 
removed by steam distillation. It was purified by dissolving 
in sodium hydroxide solution, filtering, followed by 
addition of hydrochloric acid. The solid so obtained was 
filtered, washed with cold water, dried and crystallized 
from methanol to give a cream colored product, which gave 
effervescence with sodium bicarbonate solution [30]. 
General procedure for the synthesis of 3-[5-(substituted 
aryl)-1, 3, 4-oxadiazol-2-yl]-1-(biphenyl-4-yl) propan-1-
ones (3a-3h) 
Benzoic acid hydrazide derivatives (0.001 mol) were 
dissolved in phosphorous oxychloride (5 mL) and to it was 
added 3 (equimolar, 0.001 mol). The reaction mixture, after 
refluxing for 2–5 h, was cooled to room temperature and 
poured onto crushed ice. On neutralization of the contents 
with sodium bicarbonate solution (20% w/v) a solid mass 
separated out which was filtered, washed with water, dried 
and recrystallized from methanol to give 3a-3h [30]. 
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Antiinflammatory activity test was performed by 
Carrageenan induced rat paw oedema model [17]. Freshly 
prepared suspension of carrageenan (0.05 mL, 1% w/v 
solution in 0.9% saline) was injected under the plantar 
aponeurosis of the right hind paw of each rat. Animals were 
divided in groups of six in each group. One groupwas kept 
as control and the animals of other groups were pre-treated 
with the test drugs suspended in 1% 
carboxymethylcellulose (CMC) given orally 30 min before 
carrageenan injection. The paw volume was measured 
before and after 4 h of carrageenan injection by 
plethysmograph. The percentage inhibition of inflammation 
was calculated by applying the following formula: 
Antiinflammatory activity (% inhibition) = (Vc – Vt) /Vc X 
100 
Where Vc = edema volume in control group, Vt = edema 
volume in groups treated with test compounds. 
Compounds 3a-3g was equipotent to fenbufen while 3h 
proved to be more potent than fenbufen, its anti-
inflammatory activity being comparable with that of 
diclofenac. Data show that the presence of 2-
naphtyloxymethyl, 4-methoxyphenyl or 3, 4-dimethoxy 
phenyl substitution at the 5 position of the oxadiazole ring 
can either maintain or improve the anti-inflammatory 
activity in this series of fenbufen derivatives [30]. 
5. SYNTHESIS AND ANTIINFLAMMATORY 
ACTIVITY OF 3-ARYL-5-DECAPENTYL-1, 2, 4-
OXADIAZOLES 
1, 2, 4-oxadiazoles having long fatty acid chain at C-5 have 
not been reported Therefore, it appeared attractive to 
undertake the synthesis of 1, 2, 4-oxadiazoles carrying a 
15-carbon sidechain at C-5. In fact, these new heterocycles 
may be considered as isosters of palmitic acid esters and 
amides which possess interesting pharmacological 
properties. For example, N-(2-hydroxyethyl)palmitamide 
(PEA) helps to prevent acute respiratory diseases (ARD) in 
men [36-38]. It has also been shown that administration of 
PEA does not have any influence on the formation of 
antibodies [36, 39]. The production of palmitic acid ethyl 
ester (PAEE) in pregnant rat and its offspring was explored 
with interesting findings [36, 40]. Work on PEA considered 
this compound as a new class of anti-inflammatory agent 
and thought that PEA (an endogenous compound) is 
accumulated at the inflammation site and helps to suppress 
it [36, 41]. Very recently, identified the nuclear receptor 
peroxisome proliferator-activated receptor-a (PPAR) which 
secures the fatty acid amide (PEA) and causes the 
inflammation reduction[36, 42]. A recent publication also 
reports the anti-inflammatory activity of tri-terpene-fatty 
acid esters and free fatty acids [36, 43]. 1, 2, 4-Oxadiazoles 
with propyl and isopropyl functions at C-5 have been found 
to possess anti-inflammatory activity [36, 44-45]. The title 
compounds 4a–f exhibited anti-inflammatory activity 
closely resembling to aspirin and ibuprofen. 
Synthesis of 3-Aryl-5-decapentyl-1, 2, 4-oxadiazoles 
(4a–f) 
An appropriate arylamidoxime 1 (1.0 mmol), palmitic acid 
2 (1.0 mmol) and dicyclohexylcarbodiimide (1.25 mmol) 
were dissolved in dichloromethane (5.0 ml) and left under 
stirring for 6 h at room temperature under nitrogen 
atmosphere. TLC (cyclohexane/ethyl acetate, 9:1) 
confirmed the consumption of all arylamidoxime. Filtration 
of dicyclohexylurea and washing the solid with a little 
dichloromethane gave a transparent solution which 
contained largely the intermediate O-
palmitoylbenzamidoxine (3a–f). Each intermediate was 
heated individually at 110 °C for about 6 h for complete 
cyclization. Further purification was achieved by passing 
the crude 1, 2, 4-oxadiazole through a column containing 
silica gel. The pure compound could be eluted with 
cyclohexane ethyl acetate (9.9:0.1). Thus, all Oxadiazoles 
4a–f have been obtained in the pure form. The yields 
furnished below are of chromatographically pure 
compounds. Oxadiazoles 4a, d–f were crystallized and 
recrystallized from chloroform–n-hexane [36]. 
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The anti-inflammatory activity was determined by Levy 
and Kerley method [46].  Three-month-old Swiss white 
mice with 25–30 g body weight were maintained with 
water and food. Ten groups, each containing 10 animals, 
were used separately for each experiment. Saline solution 
(0.9%) was administered to the control group. The drugs 
used for comparison purposes were aspirin and ibuprofen. 
All compounds were suspended in 1% 
carboxymethylcellulose (CMC) dissolved in water and a 
single dose of 250 mg kg-1 was administered 
intraperitoneally in the morning. Other animal group 
received 1% CMC only. Two positive and one negative 
anti-inflammatory test were done in three animal groups by 
intraperitoneal administration of 250 mg kg–1 of aspirin  
[47], in the first group, 250 mg kg–1 of ibuprofen in the 
second group and 0.9% of aqueous saline solution in the 
third group, respectively.. A 0.1 ml of 1% carrageenin  in 
0.9% aqueous NaCl solution was injected through the 
plantar tissue of the right hind paw of each mouse to 
produce inflammation. The test compounds were injected 
intraperitoneally 30 min later. After 4 h, their paws were 
cut and weighed. The results were analyzed according to 
the percentage of inflammation reduction.  
All six compounds 4a–f are non-lethal in mice at four times 
the therapeutic dose (i.p., LD50 > 1 g kg–1). Preliminary 
anti-inflammatory activity tests for compounds 4a–f 
exhibited positive results. Oxadiazoles 4a, 4e and 4f 
reduced carrageenan-induced edema in mice by 29, 33 and 
34%, respectively. This result is significant (P < 0.05) 
compared to the control group treated with saline solution. 
However, compounds 4b, 4c and 4d, which have a ortho-, 
meta- and para-substituent in the phenyl ring did show a 
significant decrease in edema (55, 67 and 67%; P < 0.001) 
greater than the control animals treated with 0.9% saline or 
1% CMC solution. Furthermore, the anti-inflammatory 
effect of compounds 4c and 4d were comparable with 
aspirin (68%) and ibuprofen (73%). Since compounds 4c 
and 4d gave the best acute anti-inflammatory activity, its 
dose–response curve was compared with ibuprofen which 
clearly shows that administration of 250 mg of compound 
4c per kg of animal’s body weight reduces the 
inflammation by 67%. This is closer to the value obtained 
by ibuprofen. Increasing the dose of 4c and 4d to 350 mg 
kg–1 of the animal’s weight slightly improves the 
performance of these heterocycles and brings the activity 
very close to ibuprofen (70 and 73%). 
6. SYNTHESIS AND ANTIINFLAMMATORY 
ACTIVITY OF NOVEL 2-(1-ADAMANTYL)-5-
SUBSTITUTED-1, 3, 4-OXADIAZOLES 
Derivatives of adamantane have long been known for their 
antiviral activity against Influenza A [48-52] and HIV 
viruses [48, 53-55]. Anti-inflammatory and antimicrobial 
activities of novel series of 3-(1-adamantyl)-substituted-1, 
2, 4-triazoline-5-thiones and 2-(1-adamantyl)-1, 3, 4-
oxadiazolin-5-thiones, carrying an acetic or propionic acid 
moiety [48, 55]. Reaction of 1-adamantanecarbonyl 
chloride with certain carboxylic acid hydrazides in pyridine 
yielded the corresponding N-acyl adamantane- 1-
carbohydrazide derivatives 3a-f, which were cyclized to the 
corresponding 2-(1-adamantyl)-5-substituted-1,3,4-
oxadiazoles 4a-f via heating with phosphorus oxychloride. 
Synthesis of 2-(1-Adamantyl)-5-substituted-1, 3, 4-
oxadiazoles 
A mixture of 1-adamantanecarbonyl chloride 1 (1.99 g, 
0.01 mol) and the appropriate carboxylic acid hydrazide 2 
(0.01 mol), in dry pyridine (10 ml), was heated under reflux 
for 30 min. On cooling, the mixture was poured onto cold 
water (50 ml) and stirred for 10 min. The separated solid 
was filtered, washed thoroughly with cold water and dried 
to yield the N-acyl adamantane-1-carbohydrazide 
derivatives 3 in 90-95% yields. The products were pure 
enough to be used in the next step without further 
purification. The appropriate compounds 3 were added to 
phosphorus oxychloride (6 ml) and the mixture was heated 
under reflux for 1 h. On cooling, crushed ice (50 g) was 
added cautiously and the mixture was stirred for 30 min. 
The separated crude product was filtered, washed with 
water then with saturated sodium hydrogen carbonate 
solution and finally with water, dried and crystallized from 
ethanol to yield compounds 4a-f [48]. 
  
Anti-inflammatory activity 
The acute anti-inflammatory activity of the synthesized 
compounds was determined following the carrageenin-
induced paw oedema method in rats [26]. Each compound 
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was tested in three dose levels: 20, 40 and 60 mg/kg. The 
results of the anti-inflammatory activity of the synthesized 
compounds and the well-known anti-inflammatory drug 
Indomethacin (10 mg/kg). The majority of the oxadiazole 
derivatives 4a-f showed significant dose-dependent anti-
inflammatory activity. The best activity was observed with 
the oxadiazole derivatives 4c, 4d, 4e and 4f which 
displayed strong dose-dependent inhibition of carrageenin-
induced oedema producing >50% inhibition at 60 mg/kg 
dose. Meanwhile, the oxadiazole derivatives 4a, 4b were 
found moderately active producing <50% inhibition of 








The oxadiazole ring is an important pharmacophore in 
modern drug discovery. In recent years, attention has 
increasingly been given to the synthesis of oxadiazole 
derivatives as a source of anti-inflammatory agents. The 
synthesis of novel oxadiazole derivatives remains a main 
focus of medicinal research. Since now, researchers have 
been attracted toward designing more potent oxadiazole 
derivatives having wide diverse of biological activity.
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